20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
October 2021 in “Journal of Investigative Dermatology” Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
2 citations
,
November 1996 in “Transplantation” Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
43 citations
,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
1 citations
,
April 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors are effective treatments for alopecia areata.
7 citations
,
December 2021 in “European Respiratory Review” The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.
IP-PA1 helps grow hair in mice and affects human cell growth-related genes differently than traditional hair growth treatments.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
July 2022 in “Media Dermato Venereologica Indonesiana” The combination of PRP and triamcinolone injections improved hair growth in a man with alopecia areata.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
9 citations
,
April 2016 in “Australasian journal of dermatology” Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.
LGF injections may improve early Peyronie's disease by reducing penile curvature and plaque size.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
16 citations
,
July 2000 in “Dermatologic surgery” The multi-injection plate is a less painful and more efficient method for treating patchy hair loss.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
September 2022 in “Journal of Ayub Medical College Abbottabad” Steroid injections are more effective than platelet rich plasma for treating patchy hair loss.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
9 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Skin ulcers from interferon may not depend on the amount given.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
1 citations
,
January 2021 in “Dermatologic Therapy” Candida antigen is an effective and promising treatment for alopecia areata.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
March 2026 in “Frontiers in Immunology” Pulsed electric field treatment may help the immune system fight liver tumors.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.